secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-07-01T23:59:59+00:00
Accession:  0000950170-24-079669
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics shareholders approve all proposals at adjourned 2024 AGM
---------------------------------------------------------------------------

- Initial June 27 meeting lacked quorum; adjourned to June 28.
- All nine ordinary resolutions passed, including re-election of five directors.
- Ratified BDO USA as independent auditor and Haysmacintyre as statutory auditor.
- Non-binding advisory vote favored annual frequency for say-on-pay.
- Votes in favor ranged from 5.7B to 6.5B of ~15.8B outstanding shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024079669/0000950170-24-079669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024079669/aktx-20240628.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-079669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer